Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01298999
Other study ID # AAAE9648
Secondary ID YFBE-001
Status Completed
Phase Phase 2
First received
Last updated
Start date June 2010
Est. completion date December 2017

Study information

Verified date November 2021
Source Columbia University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to determine whether treatment with an experimental drug called YF476 in patients with Barrett's esophagus reduces the expression of tissue markers that are associated with an increased risk of developing esophageal cancer.


Description:

The association between gastro-esophageal reflux disease (GERD) and cancer of the esophagus is well-established. Barrett's esophagus (BE) is a condition in which the lining of the part of the esophagus changes to look like small intestine, and this change occurs in the setting of GERD. Patients with BE are at increased risk for developing esophageal cancer. It is recommended that all patients with BE take medicines called proton pump inhibitors (PPIs), which greatly reduce the acid produced by the stomach, in the hopes of reducing the risk of esophageal cancer. However, by reducing the acid level in the stomach, levels of a hormone called gastrin are increased. There is laboratory data to suggest that gastrin may have effects that actually promote the development of cancer, including esophageal cancer. The investigators previously showed that BE patients with very high gastrin levels are more likely to have either advanced precancerous changes (also called high grade dysplasia) or cancer of the esophagus. As such, the obvious question is raised: does gastrin promote the development of cancer in BE? YF476 is a new drug that blocks the effects of gastrin. Trials in healthy subjects have demonstrated that the drug is safe and well-tolerated. The investigators therefore propose to conduct a randomized placebo-controlled trial of YF476 in patients with Barrett's esophagus. The primary hypothesis is that treatment with YF476 will reduce the expression of tissue markers that are associated with an increased risk of developing esophageal cancer.


Recruitment information / eligibility

Status Completed
Enrollment 27
Est. completion date December 2017
Est. primary completion date December 2017
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Age >= 18 years, with histologically confirmed diagnosis of Barrett's Esophagus without dysplasia - Minimum of 1 cm circumferential Barrett's mucosa on endoscopy or at least 2 cm maximal contiguous extent of Barrett's mucosa - Proton pump inhibitor use at least once daily for at least twelve months prior to enrolment, and stable dose of PPI for the three months before enrolment - ECOG performance status = 2 and Karnofsky = 60% - Normal organ and marrow function - Use of adequate contraception during the study - Willingness to comply with all treatment and follow up procedures - Ability to understand and the willingness to sign a written informed consent document - Up to date with all age appropriate cancer screening tests, as per American Cancer Society guidelines Exclusion Criteria: - Histologically confirmed BE with high grade dysplasia, invasive carcinoma of the esophagus, low grade dysplasia - Prior endoscopic therapy for BE - History of esophageal or gastric surgery - History of atrophic gastritis, pernicious anemia, or Zollinger-Ellison syndrome - Participation in a trial of an investigational medicinal product within the previous 28 days - Prolonged QTc interval >450 msec - History of allergic reactions attributed to compounds of similar chemical composition to YF476 - History of baseline findings of: diabetes mellitus requiring insulin therapy; pancreatitis; hepatitis B, hepatitis C or HIV; malabsorption syndrome or inability to swallow or retain oral medicine; major surgery = 28 days prior to enrollment; ECOG performance status = 2; or another cancer within 3 years except for basal carcinoma of the skin or cervical carcinoma in situ; any clinically significant and uncontrolled major morbidity - Certain medicines and herbal remedies taken during the 7 days before the start of study drug - Has evidence of cancer at the time of enrolment, or has surveillance tests planned within 21 weeks after enrollment

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
YF476
25 mg: one capsule to be taken by mouth once daily for 12 weeks.
Placebo
Matching placebo: one capsule to be taken by mouth once daily for 12 weeks.

Locations

Country Name City State
United Kingdom National Institute for Health Research Cambridge
United States New York Presbyterian Hospital - Columbia New York New York

Sponsors (2)

Lead Sponsor Collaborator
Columbia University Trio Medicines Ltd.

Countries where clinical trial is conducted

United States,  United Kingdom, 

References & Publications (1)

Abrams JA, Del Portillo A, Hills C, Compres G, Friedman RA, Cheng B, Poneros J, Lightdale CJ, De La Rue R, di Pietro M, Fitzgerald RC, Sepulveda A, Wang TC. Randomized Controlled Trial of the Gastrin/CCK(2) Receptor Antagonist Netazepide in Patients with — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Mean Ki67 Expression The study is designed to examine change in tissue Ki67 expression, a marker of cellular proliferation. Up to 3 months from baseline
Primary Number of Participants That Experienced Change in Any Biomarker Expression Participants with changes in gene expression were assessed by RNA-sequencing (i.e., sample has sufficient RNA for analysis) between baseline and up to 3 months are tallied. Up to 3 months from baseline
Secondary Number of Participants That Experienced Adverse Events A measure of safety and tolerability. Participants with recorded adverse events were tallied. The events include any adverse events and/or severe adverse events. Up to 4 months from baseline
See also
  Status Clinical Trial Phase
Active, not recruiting NCT02864043 - Barrett's Dysplasia Detection Pilot Trial Using the NvisionVLE® Imaging System N/A
Recruiting NCT02018367 - Accuracy, Yield and Clinical Impact of a Low-Cost HRME in the Early Diagnosis of Esophageal Adenocarcinoma Phase 2
Terminated NCT01572987 - Endoscopic Resection or Ablation for Patients With Dysplasia or Cancer Requiring Treatment of Barrett's Esophagus N/A
Terminated NCT01976351 - Imaging Enhanced Endoscopy for the Screening of Barrett's Esophagus N/A
Terminated NCT00526786 - Study of CryoSpray Ablation of Low Grade or High Grade Dysplasia Within Barrett's Esophagus Phase 4
Completed NCT01401699 - Optical Coherence Tomography (OCT) Based Screening of Esophagus and Gastroesophageal Junction N/A
Completed NCT02106910 - Non-Endoscopic Surveillance for Barrett's Esophagus Following Ablative Therapy N/A
Suspended NCT01580631 - Narrow Band Imaging Project on Barrett's Esophagus
Completed NCT01439633 - Optical Frequency Domain Imaging (OFDI) Surveillance and Image Guided Biopsy of the Esophagus N/A
Completed NCT02879721 - Expression and Function of the Renin-Angiotensin System in the Esophagus Phase 0
Completed NCT01439594 - Optical Frequency Domain Imaging (OFDI) Assessment in Radiofrequency Ablation N/A
Completed NCT01281618 - Influence of Acid Reflux on Stromal Epithelial Interaction in Barrett's Esophagus N/A
Completed NCT00844077 - Preliminary Longitudinal Validation of Biomarkers Predictive of Barrett's Esophagus N/A
Completed NCT00586872 - Endoscopic Mucosal Resection (EMR) in Barrett's Esophagus
Completed NCT00588575 - Ramanspectroscopy in Barrett's Esophagus
Recruiting NCT00288119 - Genetic Determinants of Barrett's Esophagus and Esophageal Adenocarcinoma
Completed NCT03813381 - CAlorie and Protein REstriction PROgram in Barrett's Esophagus Patients (CARE-PRO). N/A
Completed NCT02579460 - Reflux-Induced Oxidative Stress in Barrett's Esophagus: Response, Repair, and Epithelial-Mesenchymal-Transition N/A
Completed NCT01961778 - Comparison of Treatments for Barrett's Esophagus With High-Grade Dysplasia/Early Adenocarcinoma N/A
Not yet recruiting NCT02033070 - Patient Registry: Radio Frequency Ablation of Barrett's Esophagus Using HALO System N/A